HCPCS Level II code J2760 denotes the injectable drug phentolamine mesylate, supplied in amounts up to 5 mg. The code is used to report the medication itself in outpatient settings where parenteral agents are administered, including physician offices, outpatient clinics, and hospital outpatient departments. Nationally, accurate coding of drug J-codes like J2760 matters for proper claims processing, cost reporting, and clinical documentation tied to pharmacologic interventions.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of payer coverage patterns and coding considerations for HCPCS Level II drug reporting, benchmarking context for utilization and reimbursement where available, and clinical context that explains typical use cases for phentolamine mesylate injections. The publication summarizes common billing modifiers used with J-codes, typical sites of service, and notes where input data was not provided.

This summary equips billing managers, revenue cycle analysts, and policy professionals with the essential facts about HCPCS Level II code J2760, helping stakeholders align documentation and claim submission practices with payer expectations and national billing norms.